SBIR Phase I: Improving cell loading efficiency for suture mediated cell therapy

SBIR 第一阶段：提高缝合介导细胞疗法的细胞装载效率

• 批准号: 1315182
• 负责人: Adam Collette
• 金额: $ 14.95万
• 依托单位: VitaThreads LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1315182&HistoricalAwards=false
• 关键词: SBIR; Phase; Improving; cell; loading

This Small Business Innovation (SBIR) Phase I project will provide critical advances in the understanding of interactions between mesenchymal stem cells and a novel fibrin microthread suture construct in an effort to overcome significant inefficiencies in the field of cell therapy delivery. This work will develop a novel seeding vessel and associated regimen for highly efficient mesenchymal stem cell loading to be applied to fibrin microthread sutures. Once such a regimen has been developed, resultant devices will be implanted intramuscularly in a rat model to explore cell delivery efficiency and host response to the cell-loaded fibrin microthread device. The resultant cell seeding data will provide insight into the extent to which cell seeding efficiency in vitro may be manipulated by simplistic modifications to common seeding conditions including vessel geometry, cell concentration, and total cell load. The in vivo work will provide critical information describing the biocompatibility of fibrin microthreads, cell delivery efficiency of syringe-mediated compared to fibrin microthread-mediated interventions, and inflammatory/fibrotic potential of these interventions respectively. In turn, the systems developed in this project will be expected to provide a platform for further research of cell therapy performed with discreetly delivered, highly viable, and accurately dosed cell populations.The broader impact/commercial potential of this project relates not only to the specific indication targeted, Achilles tendon, but more broadly to other connective tissue repairs, other enhanced healing indications, and other cell delivery applications. Once fully realized, the Achilles tendon repair augmentation market alone is projected to be worth $500M annually in the United States. While the suture-like form factor may not be ideal for all applications, several types of open surgeries performed upon poorly healing or non-healing organ systems could readily benefit from cell delivery by this technology. This would include indications such as myocardial infarct repair, neural tissue regeneration in cases of stroke, and cochlear tissue regeneration. The successful commercialization of our project represents a significant step forward in tissue engineering and next generation cell-based medicines, promising to improve both longevity and quality of life for countless people.

这个小企业创新（SBIR）第一阶段项目将在理解间充质干细胞和新型纤维蛋白微线缝合结构之间的相互作用方面取得重大进展，以克服细胞治疗领域中明显的低效率问题。这项工作将开发一种新型的接种容器和相关方案，用于高效加载间充质干细胞，并将其应用于纤维蛋白微线缝合线。一旦开发出这样的方案，所得装置将被肌内植入大鼠模型中，以探索细胞递送效率和宿主对装载细胞的纤维蛋白微线装置的反应。由此产生的细胞接种数据将深入了解体外细胞接种效率可通过对常见接种条件（包括容器几何形状、细胞浓度和总细胞负荷）进行简单修改来控制的程度。体内工作将提供关键信息，描述纤维蛋白微线的生物相容性、注射器介导的细胞递送效率与纤维蛋白微线介导的干预措施相比，以及这些干预措施的炎症/纤维化潜力。反过来，该项目开发的系统预计将为进一步研究采用谨慎递送、高度存活且准确剂量的细胞群进行细胞疗法提供一个平台。该项目更广泛的影响/商业潜力不仅涉及特定的目标适应症，跟腱，而且更广泛地涉及其他结缔组织修复、其他增强愈合适应症和其他细胞递送应用。一旦完全实现，美国仅跟腱修复增强市场预计每年价值 5 亿美元。虽然类似缝合线的形状因素可能并不适合所有应用，但在愈合不良或不愈合的器官系统上进行的几种类型的开放手术可以很容易地受益于该技术的细胞输送。这将包括心肌梗塞修复、中风时的神经组织再生和耳蜗组织再生等适应症。我们项目的成功商业化代表了组织工程和下一代细胞药物的重大进步，有望提高无数人的寿命和生活质量。